StockData
IGC Pharma, Inc. logo

IGC Pharma, Inc. (IGC) stock

IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3019% above fair value
$0.19+0.01 (+7.37%)

Close on Nov 17, 2026Market cap $19.43MP/E –Yield –

IGC Pharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

IGC Pharma's operating income for the twelve months ending Jun 30, 2026 was -$11.08M. For fiscal 2025 it was -$7.45M. The highest annual figure on record is -$1.79M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Mar 31, 2025-$7.45M–
FY2024Mar 31, 2024-$9.80M–
FY2023Mar 31, 2023-$11.57M–
FY2022Mar 31, 2022-$15.43M–
FY2021Mar 31, 2021-$8.72M–
FY2020Mar 31, 2020-$6.86M–
FY2019Mar 31, 2019-$4.64M–
FY2018Mar 31, 2018-$1.79M–
FY2017Mar 31, 2017-$2.05M–
FY2016Mar 31, 2016-$2.91M–
FY2015Mar 31, 2015-$4.34M–
FY2014Mar 31, 2014-$2.53M–
FY2013Mar 31, 2013-$2.48M–
FY2012Mar 31, 2012-$7.51M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026-$2.78M–
Q4 FY2026CQ1 2026Mar 31, 2026-$2.46M–
Q3 FY2026CQ4 2025Dec 31, 2025-$2.94M–
Q2 FY2026CQ3 2025Sep 30, 2025-$2.90M–
Q1 FY2026CQ2 2025Jun 30, 2025-$1.91M–
Q4 FY2025CQ1 2025Mar 31, 2025-$1.41M–
Q3 FY2025CQ4 2024Dec 31, 2024-$1.88M–
Q2 FY2025CQ3 2024Sep 30, 2024-$1.76M–
Q1 FY2025CQ2 2024Jun 30, 2024-$2.40M–
Q4 FY2024CQ1 2024Mar 31, 2024-$2.17M–
Q3 FY2024CQ4 2023Dec 31, 2023-$3.00M–
Q2 FY2024CQ3 2023Sep 30, 2023-$2.49M–
Q1 FY2024CQ2 2023Jun 30, 2023-$2.14M–
Q4 FY2023CQ1 2023Mar 31, 2023-$4.04M–
Q3 FY2023CQ4 2022Dec 31, 2022-$2.28M–
Q2 FY2023CQ3 2022Sep 30, 2022-$2.49M–
Q1 FY2023CQ2 2022Jun 30, 2022-$2.80M–
Q4 FY2022CQ1 2022Mar 31, 2022-$6.50M–
Q3 FY2022CQ4 2021Dec 31, 2021-$2.39M–
Q2 FY2022CQ3 2021Sep 30, 2021-$4.35M–
Q1 FY2022CQ2 2021Jun 30, 2021-$2.19M–
Q4 FY2021CQ1 2021Mar 31, 2021-$2.79M–
Q3 FY2021CQ4 2020Dec 31, 2020-$2.33M–
Q2 FY2021CQ3 2020Sep 30, 2020-$1.68M–
Q1 FY2021CQ2 2020Jun 30, 2020-$1.93M–
Q4 FY2020CQ1 2020Mar 31, 2020-$2.44M–
Q3 FY2020CQ4 2019Dec 31, 2019-$1.68M–
Q2 FY2020CQ3 2019Sep 30, 2019-$1.29M–
Q1 FY2020CQ2 2019Jun 30, 2019-$1.46M–
Q4 FY2019CQ1 2019Mar 31, 2019-$1.70M–
Q3 FY2019CQ4 2018Dec 31, 2018-$1.58M–
Q2 FY2019CQ3 2018Sep 30, 2018-$855.00K–
Q1 FY2019CQ2 2018Jun 30, 2018-$511.00K–
Q4 FY2018CQ1 2018Mar 31, 2018-$714.00K–
Q3 FY2018CQ4 2017Dec 31, 2017-$473.00K–
Q2 FY2018CQ3 2017Sep 30, 2017-$263.00K–
Q1 FY2018CQ2 2017Jun 30, 2017-$396.27K–
Q4 FY2017CQ1 2017Mar 31, 2017-$735.10K–
Q3 FY2017CQ4 2016Dec 31, 2016-$386.11K–
Q2 FY2017CQ3 2016Sep 30, 2016-$549.63K–

More IGC Pharma figures

See a number that looks wrong?